Donor Lymphocyte Infusion Post-Transplant

Preemptive Infusion of Donor Lymphocytes Depleted of TCR (Alpha-beta) + T Cells and CD19+ B Cells Following Allogeneic Stem Cell Transplantation

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 1
Enrollment
10 patients (estimated)
Sponsors
Case Comprehensive Cancer Center
Tags
Donor Lymphocyte Infusion (DLI)
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1590
NCT Identifier
NCT03939585

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.